MiMedx Group Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

MiMedx Group hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

0.05%

Rückkaufsrendite

Gesamte Aktionärsrendite	0.05%
Zukünftige Dividendenrendite	n/a
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease

Nov 21

There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise

Nov 06

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

May 21

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

May 14

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Mar 27

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Jan 05

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 18

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von MDXG in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von MDXG gestiegen sind.

Dividendenrendite im Vergleich zum Markt

MiMedx Group Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von MDXG im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (MDXG)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.3%
Branchendurchschnitt (Biotechs)	2.3%
Analystenprognose (MDXG) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von MDXG im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von MDXG im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von MDXG, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da MDXG keine Ausschüttungen gemeldet hat.

MiMedx Group Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease

Investor sentiment improves as stock rises 21%

New minor risk - Share price stability

Investor sentiment improves as stock rises 32%

There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise

MiMedx Group, Inc. Raises Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Consensus EPS estimates fall by 10%

New major risk - Revenue and earnings growth

MiMedx Group, Inc. Provides Sales Guidance for the Full Year of 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

MiMedx Group, Inc. Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature- Scientific Reports

MiMedx Group, Inc. to Report Q2, 2024 Results on Jul 31, 2024

MiMedx Group, Inc. Announces the Appointment of Kim Moller to Chief Commercial Officer

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Investor sentiment improves as stock rises 18%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc., Annual General Meeting, Jun 05, 2024

MiMedx Group, Inc. to Report Q1, 2024 Results on Apr 30, 2024

MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation (RFD) from FDA

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Insider recently sold US$162k worth of stock

Mimedx Introduces E-Commerce and Account Management Platform

MiMedx Group, Inc. Announces Appointment of New Independent Directors

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Insider selling

Insider recently sold US$250k worth of stock

MiMedx Group, Inc. to Report Q4, 2023 Results on Feb 28, 2024

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Mimedx Group, Inc. Announces Launch of Epieffect

Mimedx Group, Inc. Announces Retirement of Mr. William Phelan as Chief Accounting Officer

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

MiMedx Group, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.01 (vs US$0.11 loss in 2Q 2022)

Price target increased by 8.0% to US$10.17

Forecast breakeven date moved forward to 2023

MiMedx Group, Inc. Announces Chief Financial Officer Changes

Consensus EPS estimates upgraded to US$0.10 loss

Price target decreased by 9.3% to US$9.29

Insider recently sold US$84k worth of stock

Insider notifies of intention to sell stock

MiMedx Group, Inc., Annual General Meeting, Jun 13, 2023

Insider recently sold US$276k worth of stock

Insider notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Insider notifies of intention to sell stock

Chief Financial Officer recently sold US$85k worth of stock

Chief Financial Officer notifies of intention to sell stock

MiMedx Group, Inc. Announces Chief Executive Officer Changes

MiMedx Group, Inc. to Report Q4, 2022 Results on Mar 01, 2023

MiMedx Group, Inc. Appoints Ricci S. Whitlow as Chief Operating Officer

Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

MiMedx Group, Inc. Announces the Resignation of Rohit Kashyap as President, Wound Care and Surgical, Effective January 3, 2023

Price target decreased to US$10.25

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. Provides Net Sales Guidance for the Fourth Quarter and Full Year 2022

MiMedx Group, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Price target decreased to US$10.25

Mimedx Group, Inc. Announces Management Changes

High number of new directors

MiMedx Group, Inc. Announces Launch of AXIOFILL

MiMedx Group, Inc. Announces Launch of AMNIOEFFECT™

Insider recently sold US$94k worth of stock

MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX

Consensus EPS estimates fall by 12%